What is Sera Prognostics?
Founded to address critical gaps in maternal healthcare, Sera Prognostics specializes in creating diagnostic tests designed for the early prediction of a woman's individual risk of premature birth, preeclampsia, and other pregnancy complications. By providing actionable insights to women and their healthcare providers, the company empowers timely and personalized treatment and care strategies. Sera Prognostics' commitment to improving outcomes for mothers and newborns positions it as a key player in the diagnostics and women's health sectors, leveraging advanced predictive analytics and biomarker research.
How much funding has Sera Prognostics raised?
Sera Prognostics has raised a total of $325M across 11 funding rounds:
Debt
$4.5M
Private Equity
$9.2M
Private Equity
$5M
Series B
$25M
Debt
$10M
Series C
$40M
Series D
$36M
Debt
$1M
Series E
$100M
Share Placement
$75M
Debt (2013): $4.5M led by InterWest Partners, Linden, UpStart Ventures, and Catalyst Health Ventures
Private Equity (2014): $9.2M, investors not publicly disclosed
Private Equity (2014): $5M, investors not publicly disclosed
Series B (2015): $25M backed by Catalyst Health Ventures, Domain Associates, Bill & Melinda Gates Foundation, and InterWest Partners
Debt (2015): $10M with participation from Square 1 Bank
Series C (2017): $40M led by Bill & Melinda Gates Foundation, InterWest Partners, Catalyst Health Ventures, Laboratory Corporation of America, and Domain Associates
Series D (2019): $36M supported by Chione , Ltd, Blue Ox Healthcare Partners, Domain Associates, InterWest Partners, Labcorp, and Catalyst Health Ventures
Debt (2020): $1M featuring PPP
Series E (2021): $100M backed by Blue Ox Healthcare Partners, Vivo Capital, Parian Global, Anthem, and aMoon
Share Placement (2021): $75M, investors not publicly disclosed
Key Investors in Sera Prognostics
Domain Associates
Domain Associates is an investment advisory firm established in 1985, specializing in biotech investments. It manages nine subsequent biotech venture capital funds and has a total of $2.8 billion in assets. The firm has provided VC funding to 194 biopharmaceutical, device, and diagnostic companies, resulting in 90 IPOs and 110 M&A events, with a combined market cap of $190 billion for the funded companies. Its intended clients include biotech startups and investors looking to enter the biotech sector.
Labcorp
Labcorp Holdings Inc. operates as a laboratory services company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Catalyst Health Ventures
Catalyst @ Health 2.0 is dedicated to enhancing the health innovation ecosystem by leveraging a global network and validated methodologies. They offer unique programs that address complex healthcare challenges and facilitate strategic partnerships between innovators and companies seeking new healthcare technologies. Their initiatives include supporting digital health innovations in response to COVID-19 and providing market-access programs for technology companies in emerging markets. The company also conducts research and surveys to analyze the impact of digital health trends on the industry.
What's next for Sera Prognostics?
With substantial enterprise-level funding and a recent strategic investment, Sera Prognostics is poised for accelerated growth. The company's trajectory suggests a focus on scaling its diagnostic test offerings, expanding its market reach, and potentially forging new partnerships within the healthcare ecosystem. Future developments may include further clinical validation, broader adoption by healthcare systems, and continued innovation in predictive diagnostics for high-risk pregnancies. The sustained backing from prominent investors indicates strong confidence in Sera Prognostics' mission and its potential to significantly impact maternal and neonatal health outcomes.
See full Sera Prognostics company page
